MyoStrain®, MyoStress™ Rapid Hyperventilation Breath-hold Maneuver Enables First-of-its-Kind Needle-Free Stress Protocol for the Accurate Detection of Myocardial Ischemia
ncarol.com/10113696

MORRISVILLE, N.C., April 28, 2021 /PRNewswire/ -- A new peer-reviewed study accepted in the Journal of the American College of Cardiology: Cardiovascular Imaging validated Myocardial Solutions ("MSI") technologies MyoStrain and MyoStress in a new stress testing protocol utilizing a hyperventilation breath-hold (HVBH) maneuver to accurately detect myocardial ischemia. The article demonstrated MyoStrain's speed and sensitivity to successfully measure cardiac stress during a safe, simple breathing maneuver. This novel technique may provide clinicians with a faster and safer quantitative stress test to help improve the diagnosis and management of coronary artery disease without any pharmacological or physical stress protocols.[1]

Results showed the MyoStrain/MyoStress HVBH maneuver yielded greater accuracy over traditional stress testing methods for the detection of myocardial ischemia. HVBH exam times were significantly shorter and were performed without contrast agents or pharmacological stressors.

Dr. Marco Ochs, MD, Cardiologist at Theresien Hospital in Mannheim, Germany and lead author of the study, stated: "This study demonstrates the immense clinical utility MyoStrain's diagnostic speed and accuracy can bring to ischemic stress testing. Hyperventilation/breath-hold maneuver combined with MyoStrain/MyoStress provides a fast and safe scan procedure for clinicians to assess their patients without needing contrast agents or pharma stressors. The result is a 15-minute, needle-free MyoStress test designed to help advance ischemia detection, improve workflow efficiency and enhance the overall patient experience."

More on ncarol.com

• Congressional Roundtable Exposes Mental Health Crisis: More Spending and Treatment, Worse Results – CCHR Demands Accountability
• Attorney Joseph C. Kreps Files Lawsuit to Stop Alabama State Board of Pharmacy's Unlawful "Revenue-First" Rulemaking
• VDG Virtuoso Continues Building Momentum for Independent Artists in the 910
• NAIDOC Week Australia 2026 | 50 Years Deadly - Celebrates Culture, Resilience, and Global Connection
• Preeclampsia and Hurricane Survivor Gives Birth at the Same Hospital Where Her Father Passed Away

Professor Matthias Friedrich, MD, FESC, FACC, MSCMR, Professor of Medicine and Chief of Cardiovascular Imaging at McGill University Health Centre in Montreal, Quebec, added: "There are numerous limitations concerning the safety, feasibility, logistical effort, and speed with today's stress testing techniques. We adapted the hyperventilation/breath-hold maneuver with MyoStrain to help overcome these limitations, providing a fast, safe and non-invasive approach to improve the cardiovascular assessment of patients suspected of coronary artery disease. This is a huge step."

John Funkhouser, CEO at MSI, stated: "There are over 10 million annual tests performed in the U.S. every year. The majority of stress testing is nuclear, which involves injecting radioactive agents into the patient. This procedure is not highly accurate and can take up to four hours of the patient's time to complete. MyoStress testing takes about 15 minutes, is totally non-invasive, and is highly accurate in finding ischemia caused by coronary heart diseases. This test could become a new standard of care in stress testing."

Access to the publication abstract is available here.

[1] Ochs, M et al. J Am Coll Cardiol Cardiovasc Imaging. Apr 14, 2021. DOI: 10.1016/j.jcmg.2021.02.022

More on ncarol.com

• PlanetAI Nature Space (PNS), certificadora Europea, lanza su plataforma EUDR-PNS Ready basada en IA, satélites y trazabilidad blockchain
• Rhealize Strategic Talent Advisory Co-Founder Dona Baker to Speak at DisruptHR YEG 15.0 in Edmonton on Hiring Innovation
• Instant IP Teams: Bringing Enterprise-Grade Collaboration to IP Protection at the Speed of Thought
• UK Financial Ltd Confirms CATEX Exchange Integration of SMPRA and LTNS 1 Ahead of Compliance-Based Trading Activation
• Ashikaga Flower Park's "Great Wisteria Festival 2026"

Media Contact
Ahmed Osman
[email protected]
919.459.9113

About Myocardial Solutions, Inc.

Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI's proprietary technology, MyoStrain®, is a 10-minute, MRI-based heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.

See original content: https://www.myocardialsolutions.com/news-article/myostrain-myostress-rapid-hyperventilation-breath-hold-maneuver-enables-first-of-its-kind-needle-free-stress-protocol-for-the-accurate-detection-of-myocardial-ischemia

SOURCE Myocardial Solutions, Inc.

Related Links

http://www.myocardialsolutions.com

---

Show All News | Disclaimer | Report Violation